explore -WSS

explore

author：Wikipedia 2025-09-30 17:05:14 - browse：38

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Medicaid, Medicare dual

Wikipedia

WSS

How the Dana

Covid vaccines: Private market messier than government rollout

Address the ethical violations that led to 'Three Identical Strangers'

House panel takes first step toward fixing drug shortages

Biogen shutters digital health group, ends Apple study, in cost cutting move

Medicaid, Medicare dual

Wikipedia

explore

hotspot

In Memoriam: Notable people who died in 2023

Intercept Pharmaceuticals sells itself for less than $1 billion

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Affirmative action in medical school literally saved lives

Transgender sports debate: Physicians say bans are health issue

Drug repurposing or repositioning? The language matters

Ionis has late

Anesthesiologist group: stop taking Ozempic before surgery

FDA advisers vote against ALS treatment from BrainStorm

leisure time

What happened to the House vote on health price transparency?

Covid vaccines: Private market messier than government rollout

WHO recommends dropping component of many flu vaccines

Fed up with FDA, ALS advocates consider a take

Biogen shutters digital health group, ends Apple study, in cost cutting move

After a drawn out lobbying fight, ARPA

knowledge

hotspot

Wikipedia

knowledge